Draper Asset Management LLC Boosts Holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Draper Asset Management LLC lifted its stake in Horizon Therapeutics Public Limited (NASDAQ:HZNP) by 30.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,404 shares of the biopharmaceutical company’s stock after purchasing an additional 1,246 shares during the quarter. Horizon Therapeutics Public accounts for approximately 0.5% of Draper Asset Management LLC’s holdings, making the stock its 22nd biggest position. Draper Asset Management LLC’s holdings in Horizon Therapeutics Public were worth $506,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Quadrant Capital Group LLC raised its position in shares of Horizon Therapeutics Public by 44.6% in the 2nd quarter. Quadrant Capital Group LLC now owns 350 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 108 shares during the last quarter. Capital Analysts LLC purchased a new position in Horizon Therapeutics Public in the 2nd quarter worth about $54,000. AllSquare Wealth Management LLC purchased a new position in Horizon Therapeutics Public in the 1st quarter worth about $55,000. Huntington National Bank raised its position in Horizon Therapeutics Public by 62.8% in the 2nd quarter. Huntington National Bank now owns 583 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 225 shares during the last quarter. Finally, Cullen Frost Bankers Inc. purchased a new position in Horizon Therapeutics Public in the 2nd quarter worth about $66,000. 87.90% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:HZNP traded up $0.79 during midday trading on Wednesday, hitting $106.96. 23,882 shares of the company traded hands, compared to its average volume of 1,604,756. The firm’s fifty day moving average is $103.16 and its 200-day moving average is $95.46. Horizon Therapeutics Public Limited has a 12-month low of $66.41 and a 12-month high of $111.70. The firm has a market capitalization of $24.16 billion, a P/E ratio of 47.12, a P/E/G ratio of 1.56 and a beta of 1.08. The company has a current ratio of 2.55, a quick ratio of 2.25 and a debt-to-equity ratio of 0.63.

Horizon Therapeutics Public (NASDAQ:HZNP) last posted its quarterly earnings results on Tuesday, August 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $0.75. Horizon Therapeutics Public had a return on equity of 27.41% and a net margin of 20.27%. The business had revenue of $832.55 million for the quarter, compared to the consensus estimate of $697.69 million. During the same quarter in the prior year, the company earned $0.40 EPS. The business’s revenue was up 79.9% compared to the same quarter last year. On average, research analysts expect that Horizon Therapeutics Public Limited will post 4.35 EPS for the current fiscal year.

A number of equities analysts have weighed in on HZNP shares. Citigroup boosted their target price on Horizon Therapeutics Public from $117.00 to $121.00 and gave the stock a “buy” rating in a research report on Thursday, August 5th. BMO Capital Markets upped their price target on shares of Horizon Therapeutics Public from $118.00 to $132.00 and gave the company an “outperform” rating in a research report on Thursday, August 5th. The Goldman Sachs Group upped their price target on shares of Horizon Therapeutics Public from $96.00 to $107.00 and gave the company a “neutral” rating in a research report on Tuesday, August 24th. Morgan Stanley upped their price target on shares of Horizon Therapeutics Public from $103.00 to $135.00 and gave the company an “overweight” rating in a research report on Thursday, August 26th. Finally, Zacks Investment Research raised shares of Horizon Therapeutics Public from a “sell” rating to a “hold” rating and set a $108.00 price target for the company in a research report on Thursday, July 29th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Horizon Therapeutics Public presently has an average rating of “Buy” and a consensus target price of $117.73.

In other Horizon Therapeutics Public news, Director Michael G. Grey sold 5,000 shares of the firm’s stock in a transaction dated Thursday, July 22nd. The stock was sold at an average price of $100.04, for a total value of $500,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Barry Moze sold 35,076 shares of the firm’s stock in a transaction dated Thursday, July 8th. The stock was sold at an average price of $92.54, for a total value of $3,245,933.04. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 95,868 shares of company stock worth $9,598,929. 3.20% of the stock is owned by corporate insiders.

About Horizon Therapeutics Public

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.

Recommended Story: Strangles

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.